Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT06365619
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — DRUG
    Two cycles of neoadjuvant ipilimumab prior to surgical resection.
  • Nivolumab — DRUG
    two cycles of neoadjuvant nivolumab prior to surgical resection.

Study Details

The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy. Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2030

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: All Patients
    Neoadjuvant Ipilimumab and Nivolumab

Primary Outcome Measure

Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery. [ Time Frame: 2 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer InstituteSalt Lake CityUtah84112
Kaitlin Stephens
[email protected]
801-213-8494
Siwen Hu-Lieskovan, PhD, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Salt Lake City, UT

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Huntsman Cancer Institute· Salt Lake City, UT

Related Studies